Banco Santander S.A. Buys 52,696 Shares of Moderna, Inc. (NASDAQ:MRNA)

Banco Santander S.A. raised its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 99.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 105,811 shares of the company's stock after purchasing an additional 52,696 shares during the period. Banco Santander S.A.'s holdings in Moderna were worth $4,400,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB grew its position in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after purchasing an additional 587 shares during the period. Venturi Wealth Management LLC raised its holdings in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after acquiring an additional 664 shares during the last quarter. Compass Planning Associates Inc bought a new position in Moderna in the 4th quarter valued at about $37,000. Larson Financial Group LLC increased its holdings in Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company's stock worth $61,000 after purchasing an additional 317 shares in the last quarter. Finally, Rakuten Securities Inc. lifted its holdings in shares of Moderna by 477.3% in the third quarter. Rakuten Securities Inc. now owns 941 shares of the company's stock valued at $63,000 after purchasing an additional 778 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. HSBC upgraded Moderna from a "hold" rating to a "buy" rating and set a $58.00 target price on the stock in a research note on Monday, November 18th. Evercore ISI set a $50.00 price objective on Moderna in a research report on Friday, February 14th. Hsbc Global Res upgraded Moderna from a "hold" rating to a "strong-buy" rating in a research note on Monday, November 18th. Bank of America lowered their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Finally, Barclays downgraded shares of Moderna from an "overweight" rating to an "equal weight" rating and decreased their price objective for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Moderna presently has a consensus rating of "Hold" and an average price target of $60.63.

Moderna Trading Down 8.0 %

Shares of Moderna stock traded down $2.89 during trading on Tuesday, hitting $33.07. The stock had a trading volume of 5,719,325 shares, compared to its average volume of 12,528,007. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The firm has a market cap of $12.76 billion, a price-to-earnings ratio of -3.56 and a beta of 1.86. The business's 50-day moving average is $36.53 and its 200 day moving average is $48.45.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.